In pursuit of accessible sickle cell cure, Novartis inks $1.5B deal to tap Precision's ARCUS gene editing tech - Endpoints News

Novartis brought in another biotech partner on its quest to create an in vivo gene editing therapy for sickle cell disease and other similar blood disorders. Tapping Precision BioSciences’ ARCUS genome editing platform, Novartis will hand over $75 million upf…

Just over a month ago, Usama Malik was indicted for giving his girlfriend, among others, insider information that ended up with her making more than $200,000 in profit. Now, she has filed a guilty pl… [+220 chars]

full article...